New Test for Early-Stage Ovarian Cancer

News
Content API Import Image_4392527792019820115

March 10, 2009 — A blood test to detect elevated levels of the proteinCA125 — combined with ultrasound — may prove to be an effective screeningstrategy for ovarian cancer in its earliest and most treatable stages, newresearch suggests.

Very early findings from the largest randomized ovarian cancer screeningstudy ever conducted are promising, researchers say.

But it will be several years until it is clear if the screening methodevaluated in the trial saves lives.

More than 200,000 postmenopausal women in the U.K. are participating in thestudy, which will end in 2014.

“These early results show that screening is feasible,” studyresearcher Usha Menon, MD, of the University College London tells WebMD.”But we don’t yet know if this screening saves lives and if so, at whatcost. The hope is that we will have these answers in 2014.”

Most Ovarian Cancers Found Late

Ovarian cancer is highly treatable when detected early, with a survival rateof 92% at least five years after being diagnosed. But more than two out ofthree patients are diagnosed with advanced-stage disease, when the five-yearsurvival rate is only 20% to 30%.

More than 21,000 new cases of ovarian cancer were diagnosed in the U.S. in2008, and more than 15,000 women died from the disease, according to AmericanCancer Society.

This is why the stakes are so high for the development of an effectivescreening strategy to detect ovarian cancer in its earliest stages, Menonsays.

The CA125 blood test, first developed in the early 1980s, measures a proteinthat is elevated in ovarian cancer patients. The second generation of the testhas proven useful for evaluating how well patients respond to ovarian cancertreatments.

But its usefulness as a screening tool to detect ovarian cancer is morecontroversial because false-positive rates tend to be high, leading tounnecessary follow-up testing and surgery.

In the U.K. study, researchers evaluated a new way of using the CA125 bloodtest, which they hope will prove more useful for diagnosing the disease.

Traditionally, a CA125 level of 35 or above has been considered elevated anda level of CA125 below this has been considered normal.

But in the risk-assessment model developed by Menon and colleagues, awoman’s absolute CA125 level is less important than changes in CA125 from yearto year. Age is also considered, since ovarian cancer risk increases withage.

CA125 Plus Ultrasound

The ongoing U.K. study includes 202,638 postmenopausal women between theages of 50 and 74 at recruitment between 2001 and 2005 who were randomlyassigned to undergo no screening, annual screening with ultrasound alone, orannual screening with ultrasound and the CA125 blood test for 10 years.

Early results from the trial show that CA125 plus ultrasound detected 90% ofthe ovarian cancers identified so far in the combined screening group, whileultrasound alone identified 75% of cancers reported in this screeninggroup.

Almost half of the cancers detected in both screening groups wereearly-stage cancers. The total number of cancers detected in the two screeninggroups was similar.

But the combined-screening group had fewer repeat tests and almost ninetimes fewer surgeries performed to confirm disease for every ovarian cancerdetected.

Thirty-five surgeries were performed to detect one cancer in the ultrasoundalone group compared to three surgeries for every cancer detected in thecombined screening group.

The study is published in the April issue of The Lancet Oncology.

American Cancer Society Director of Cancer Screening Robert A. Smith, PhD,says final results from the U.K. trial, along with as yet unpublished resultsfrom a study conducted by the National Cancer Institute, should reveal moreabout whether CA125 and ultrasound will prove useful for routine screening.

“For two decades we have been exploring ways to effectively use CA125and ultrasound to screen for ovarian cancer,” he says. “If thesestudies conclude that these new methods of using these tools have a favorablebenefit-to-harm ratio, routine screening for ovarian cancer may become areality for postmenopausal women.”

Copyright 2020 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Mobile Apps DMB_1503428499636.png

Trending Now